Bowen Hanes & Co’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $210K | Hold |
1,510
| – | – | 0.01% | 150 |
|
|
2026
Q1 | $210K | Sell |
1,510
-1,510
| -50% | -$211K | 0.01% | 150 |
|
|
2025
Q4 | $371K | Buy |
+3,020
| New | +$367K | 0.01% | 139 |
|
|
2024
Q3 | – | Sell |
-4,510
| Closed | -$309K | – | 154 |
|
|
2024
Q2 | $309K | Sell |
4,510
-4,395
| -49% | -$293K | 0.01% | 135 |
|
|
2024
Q1 | $652K | Hold |
8,905
| – | – | 0.02% | 121 |
|
|
2023
Q4 | $721K | Buy |
8,905
+5,040
| +130% | +$392K | 0.02% | 114 |
|
|
2023
Q3 | $290K | Sell |
3,865
-5,700
| -60% | -$438K | 0.01% | 131 |
|
|
2023
Q2 | $737K | Sell |
9,565
-14,920
| -61% | -$1.19M | 0.02% | 110 |
|
|
2023
Q1 | $2.03M | Buy |
24,485
+6,710
| +38% | +$556K | 0.07% | 85 |
|
|
2022
Q4 | $1.53M | Buy |
+17,775
| New | +$1.41M | 0.05% | 100 |
|
|
2017
Q4 | – | Sell |
-4,175
| Closed | -$338K | – | 143 |
|
|
2017
Q3 | $338K | Sell |
4,175
-3,065
| -42% | -$234K | 0.02% | 130 |
|
|
2017
Q2 | $512K | Sell |
7,240
-856
| -11% | -$57K | 0.03% | 119 |
|
|
2017
Q1 | $550K | Sell |
8,096
-365
| -4% | -$25.7K | 0.03% | 115 |
|
|
2016
Q4 | $606K | Sell |
8,461
-2,880
| -25% | -$214K | 0.03% | 112 |
|
|
2016
Q3 | $897K | Buy |
11,341
+485
| +4% | +$39.4K | 0.05% | 103 |
|
|
2016
Q2 | $906K | Buy |
10,856
+1,405
| +15% | +$125K | 0.05% | 100 |
|
|
2016
Q1 | $868K | Sell |
9,451
-16,515
| -64% | -$1.49M | 0.05% | 98 |
|
|
2015
Q4 | $2.63M | Sell |
25,966
-212,438
| -89% | -$22.1M | 0.15% | 83 |
|
|
2015
Q3 | $23.4M | Sell |
238,404
-22,255
| -9% | -$2.47M | 1.35% | 32 |
|
|
2015
Q2 | $30.5M | Sell |
260,659
-33,202
| -11% | -$3.63M | 1.52% | 17 |
|
|
2015
Q1 | $28.8M | Buy |
293,861
+20
| +0% | +$2.03K | 1.39% | 24 |
|
|
2014
Q4 | $27.7M | Sell |
293,841
-52,225
| -15% | -$5.4M | 1.36% | 28 |
|
|
2014
Q3 | $36.8M | Sell |
346,066
-58,325
| -14% | -$5.71M | 1.8% | 5 |
|
|
2014
Q2 | $33.5M | Buy |
404,391
+12,221
| +3% | +$951K | 1.56% | 12 |
|
|
2014
Q1 | $27.8M | Sell |
392,170
-43,720
| -10% | -$3.43M | 1.34% | 25 |
|
|
2013
Q4 | $32.7M | Sell |
435,890
-99,455
| -19% | -$6.93M | 1.59% | 10 |
|
|
2013
Q3 | $33.7M | Sell |
535,345
-95,020
| -15% | -$5.68M | 1.72% | 9 |
|
|
2013
Q2 | $32.3M | Buy |
+630,365
| New | +$32.9M | 1.73% | 10 |
|
Other funds holding GILD
Bowen Hanes & Co's GILD Position: Q2 2026 in Review
Bowen Hanes & Co held its Gilead Sciences (GILD) position steady in Q2 2026 at 1,510 shares worth $210K. The position accounts for 0.01% of the portfolio, ranked #150.
Bowen Hanes & Co first reported a position in GILD in Q2 2013 and has held it in 28 quarters since. The position peaked at $36.8M in Q3 2014. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Bowen Hanes & Co held 1,510 shares of Gilead Sciences worth $210K as of Q2 2026.
- Bowen Hanes & Co left its Gilead Sciences share count unchanged in Q2 2026.
- Gilead Sciences made up 0.01% of Bowen Hanes & Co's portfolio in Q2 2026, its #150 holding.
- Bowen Hanes & Co first reported a position in Gilead Sciences in Q2 2013 and has held it in 28 quarters since.
- Bowen Hanes & Co's Gilead Sciences position peaked at $36.8M in Q3 2014.
- 2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Bowen Hanes & Co's 13F filing for Q2 2026, filed 13 Aug 2026.